Leading Clinical Experts Discuss Advancing Personalized Breast
Cancer Screening and Detection with Newly Launched ProFound AI Risk


Added Market Growth Opportunity Presented by Pioneering AI Breast
Cancer Risk Offering


Webinar Taking Place on Monday, December 7 @ 11am ET


NASHUA, N.H. – December 3, 2020 –  iCAD,
Inc. (NASDAQ: ICAD), a global
medical technology leader providing innovative cancer detection and therapy
solutions, today announced that it will host
a key opinion leader (KOL) webinar for investors on its expanded ProFound AI®
portfolio, including its recently introduced breast cancer risk-assessment
solution that is helping transform breast cancer screening from age-based
screening to risk-adaptive precision screening, on Monday, December 7, 2020,
from 11:00 AM – 1:00 PM Eastern Time.


The call will feature
presentations by KOLs, Per Hall, MD, PhD (Karolinska Institutet), Axel
Gräwingholt, MD (Radiologie am Theater), Joshua A. Nepute, MD (Indiana
University Health-Arnett), and Emily F. Conant, MD (University of Pennsylvania
Perelman School of Medicine), who will discuss the current landscape for
digital breast tomosynthesis (DBT) and the potential for iCAD’s recently
introduced ProFound AI Risk, the first and only commercially available clinical
decision support tool that provides an accurate two-year breast cancer risk
estimation based solely on a screening mammogram. In September 2020, compelling
research published in Radiology concluded that the ProFound AI Risk model is
effective at identifying women at high likelihood of being diagnosed with
breast cancer within two years of a negative screening mammogram and in
possible need of supplemental screening.


Drs. Gräwingholt, Hall, Nepute,
and Conant will be available to answer questions following the formal


iCAD’s management team will also provide
an update on the comprehensive ProFound AI technology platform. ProFound AI for
DBT, or 3D mammography, is a high-performing workflow solution featuring the
latest in deep-learning artificial intelligence capabilities. Intended to be
used by radiologists reviewing DBT images, ProFound AI rapidly and accurately
analyzes each individual image or slice and identifies potentially malignant
lesions. Trained with one of the largest available 3D image datasets, ProFound
AI provides radiologists with crucial information, such as lesion Certainty of
Finding and Case Scores, which assist in clinical decision-making and
prioritizing caseloads.


To register for the webinar, please click here.


Per Hall, MD, PhD, is a medical
oncologist by training. He works at the Department of Medical Epidemiology and
Biostatistics at the Karolinska Institute in Stockholm, Sweden. Dr. Hall is
also an honorary consultant physician at the Department of Oncology,
Södersjukhuset, Stockholm, Sweden. His research interest is focused on breast
cancer screening and prevention. Over the last 10 years, Dr. Hall has
established the Karma Cohort, a prospective screening cohort of approximately
70,000 women.


Axel Gräwingholt, MD, is head of
the department of mammography screening in the “Radiologie am Theater”
practice in Paderborn, Germany. He has 28 years of experience in breast imaging,
reading 10,000 to 15,000 mammograms per year, and 10 years of tomosynthesis
experience in diagnostic mammography. Dr. Gräwingholt is currently co-chair of
the ECIBC’s (European Commission Initiative on Breast Cancer) Guidelines
Development Group.


Joshua Nepute, MD, is a
Diagnostic Radiology Specialist in West Lafayette, Indiana. He graduated with
honors from Vanderbilt University School of Medicine in 2008. Having more than
12 years of diverse experiences in diagnostic radiology, Dr. Nepute affiliates
with many hospitals, including Indiana University Health-Arnett.


Emily F. Conant, MD, is a
professor of Radiology, Division of Breast Imaging and the Vice Chair of
Faculty Development in the Department of Radiology at the University of
Pennsylvania, Perelman School of Medicine. She is an internationally known
clinician and researcher in the field of breast imaging, publishing over 180
peer-reviewed articles on topics ranging from novel imaging technologies,
disparities in the access to imaging, the importance of “local culture”
in mentoring and work-life integration. Dr. Conant’s breast imaging research
has focused on imaging techniques, such as DBT and the quantitative analysis of
multi-modality breast images to guide tailored, personalized screening. At
Penn, she was awarded the 2013 “FOCUS Award for the Advancement of Women
in Medicine” and named to the inaugural group of “The Academy of
Master Clinicians.”


About iCAD, Inc.

Headquartered in Nashua, NH, iCAD is a global medical technology leader providing
innovative cancer detection and therapy solutions. For more information,
visit www.icadmed.com.


“Safe Harbor” Statement under the Private Securities
Litigation Reform Act of 1995

Certain statements contained in this News Release constitute “forward-looking
statements” within the meaning of the Private Securities Litigation Reform
Act of 1995. For
example, when the Company discusses the potential of ProFound AI Risk and its
relationship with Change Healthcare, the benefits of the Company’s products,
and clinical plans and updates, it is using forward-looking statements.  Such forward-looking statements involve a
number of known and unknown risks, uncertainties and other factors which may
cause the actual results, performance or achievements of the Company to be
materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Such factors include,
but are not limited, to the Company’s ability to achieve business and strategic
objectives, increase sales and acceptance of products, adoption by CMS of a new
payment model, and that such model will prove beneficial to the Company, which
is not assured, implement expansion plans, the risks of uncertainty of patent
protection, the impact of supply and manufacturing constraints or difficulties,
uncertainty of future sales levels, protection of patents and other proprietary
rights, the impact of supply and manufacturing constraints or difficulties,
product market acceptance, possible technological obsolescence of products,
increased competition, to successfully defend itself in litigation matters,
government regulation, changes in Medicare or other reimbursement policies,
risks relating to our existing and future debt obligations, competitive
factors, the effects of a decline in the economy or markets served by the Company;
the effects of a global pandemic, and other risks detailed in the Company’s
filings with the Securities and Exchange Commission. The words “believe,”
“demonstrate,” “intend,” “expect,” “estimate,”
“will,” “continue,” “anticipate,” “likely,”
“seek,” and similar expressions identify forward-looking statements.
Readers are cautioned not to place undue reliance on those forward-looking
statements, which speak only as of the date the statement was made. The Company
is under no obligation to provide any updates to any information contained in
this release. For additional disclosure regarding these and other risks faced
by iCAD, please see the disclosure contained in our public filings with the
Securities and Exchange Commission, available on the Investors section of our
website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.




Media Inquiries:

Amy Cook, iCAD 




Investor Relations:

Jeremy Feffer, LifeSci Advisors

+ 1-212-915-2568